Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(II) dinitrate

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 955-959

  Baek, Min Son ^a   Rho, Young Soo ^a   Jung, Jee Chang ^a   Chang, Sung Goo ^b   Nomura, Masaaki ^c   Miyamoto, Ken Ichi ^c,d  

^a Kyung Hee University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c HOKURIKU UNIVERSITY   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Antitumor activity; Cisplatin; KHPC 001; LLC PK1 cells; Nephrotoxicity; P388 cells; Platinum complex

Indexed keywords

CISPLATIN; KHPC 001; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA CROSS LINKING; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LD 50; LEUKEMIA P 388; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; KIDNEY; LEUKEMIA P388; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; ORGANOPLATINUM COMPOUNDS;

EID: 0030893164     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Cleare MJ, Hydes PC and Crooke ST: Antileukemic (L1210) activity and toxicity of cis-"dichlorodiammineplatinum (II) analogs. Cancer Treat Rep 63:1503-1508,1979.
2. Prestayko AW, D'Aoust JC, Issell BF and Crooke ST: Cisplatin (cisdiamminedichloroplatinum II). Cancer Treat Rev 6:17 -39,1979.
3. Madias NE and Harrington JT: Platinum nephrotoxicity. Am J Med 65:307-314,1978.
4. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan VL and Wolpert-DeFilippes MK: Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum(IV) stereoisomers of 1,2-diaminocyclohexane. Cancer Treat Rep 70: 997-1002,1986.
5. Mathe G, Kidani Y, Noji M, Maral R, Bourut C and Chenu E: Antitumor activity of 1-OHP in mice. Cancer Lett 27:135-143, 1985.
6. Engineer MS, Ho DHW, Khokhar AR, Newman RA and Bulger RE: A comparison of the effects of cisplatin and N-methyliminodiacetato(1,2 diaminocyclohexane)platinum(II) on renal function and gentamycin excretion in rats. Toxicology 47: 307-315,1987.
7. Kizu R, Higashi S, Kidimi Y and Miyazaki M: Pharmacokinetics of (lR,2R-diaminocyclohexane)oxalato-platinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31: 475-480, 1993.
8. Burchenal JH, Kalaher K, Dew K and Lokys L: Rationale for development of platinum analogs. Cancer Treat Rep 63: 1493-1497, 1979
9. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modified rate compared with constant rate. J Natl Cancer Inst 82: 1046-1050, 1990.
10. 3 exhibiting antitumor activity and nephrotoxicity. Korean J Pharmacol 29: 283-295,1993.
11. Chang S-G, Kwon DU, Kim JI, Jung JC, Rho YS and Huffman RM: New platinum complex compounds with reduced nephrotoxicity discovered in long-term histoculture of human renal cortical tissue. Anticancer Res 15: 675-681,1995.
12. Tashiro T and Sato Y: Characterization of acquired resistance to cisdiamminedichloroplatinum(II) in mouse leukemia cell lines. Jpn J Cancer Res 83: 219-225, 1992.
13. Siram R and Ali-Osman F: Si-nuclease enhancement of the ethidium bromide binding assay of drug-induced DNA inter-strand crosslinking in human brain tumor cells. Anal Biochem 187: 345-348,1990.
14. Yoshida M, Khokhar AR, Kido Y, Ali-Oman F and Siddik ZH: Correlation of total and interstrand DNA adduct in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cisdiammine/cyclohexylaminedichloroplatinum and cisplatin. Biochem Pharmacol 48: 793-799,1994.
15. Inagaki K and Kidani Y: Differences in binding of (1,2cyclohexanediamine)platinum(II) isomers with d(GpG). Inorg Chem 25: 1-3,1986.
16. Inagaki K, Ninomiya C and Kidani Y: Interaction of DNA with antitumor active platinum complexes. Platinum complexes involving meso diamine ligand gave two Pt-d(GpG) adducts. Chem Lett 233-236,1986.
17. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M and Brabec V: Biophysical analysis of DNA modified by 1,2diaminocyclohexane paltinum(II) complexes. NucleicAcids Res 20: 267-272,1992.
18. Mauldin SK, Gibbons G, Wyrick SD and Chaney SG: Intracellular biotransformation of platinum compounds with the 1,2diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 48: 5136-5144, 1988,
19. Carfagna PF, Poma A, Wyrick S, Holbrook DJ and Chaney SG: Comparisons of tetrachloro(d,l-trans)l,2-diaminocyclohexane-platinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses. Cancer Chemother Pharmacol 27: 335-341, 1991.
20. Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD and Trump DL: Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a Phase-I clinical trial. Cancer Chemother Pharmacol 33: 347-354, 1994.